| Evasion of CD8+ T Cells Is Critical for Superinfection by Cytomegalovirus SG Hansen, CJ Powers, R Richards, AB Ventura, JC Ford, D Siess, ... Science 328 (5974), 102-106, 2010 | 353 | 2010 |
| Cytomegalovirus immune evasion C Powers, V DeFilippis, D Malouli, K Früh Human cytomegalovirus, 333-359, 2008 | 251 | 2008 |
| Rhesus CMV: an emerging animal model for human CMV C Powers, K Früh Medical microbiology and immunology 197 (2), 109-115, 2008 | 159 | 2008 |
| A structural basis for the assembly and functions of a viral polymer that inactivates multiple tumor suppressors HD Ou, W Kwiatkowski, TJ Deerinck, A Noske, KY Blain, HS Land, ... Cell 151 (2), 304-319, 2012 | 97 | 2012 |
| Phosphatidylserine exposure controls viral innate immune responses by microglia Y Tufail, D Cook, L Fourgeaud, CJ Powers, K Merten, CL Clark, ... Neuron 93 (3), 574-586. e8, 2017 | 78 | 2017 |
| Rhesus cytomegalovirus contains functional homologues of US2, US3, US6, and US11 NT Pande, C Powers, K Ahn, K Früh Journal of virology 79 (9), 5786-5798, 2005 | 78 | 2005 |
| Signal peptide-dependent inhibition of MHC class I heavy chain translation by rhesus cytomegalovirus CJ Powers, K Früh PLoS pathogens 4 (10), e1000150, 2008 | 50 | 2008 |
| Selective cell targeting using adenovirus and chemical dimers C O'shea, S Miyake-Stoner, C Powers | 25* | 2013 |
| CMV glycoproteins and recombinant vectors L Picker, K Frueh, SG Hansen, C Powers US Patent 10,101,329, 2018 | 24* | 2018 |
| Adenoviral tumor diagnostics C O'shea, C Powers US Patent 9,885,090, 2018 | 22 | 2018 |
| Olgotrelvir, a dual inhibitor of SARS-CoV-2 Mpro and cathepsin L, as a standalone antiviral oral intervention candidate for COVID-19 L Mao, N Shaabani, X Zhang, C Jin, W Xu, C Argent, Y Kushnareva, ... Med 5 (1), 42-61. e23, 2024 | 19 | 2024 |
| The cytoplasmic domain of rhesus cytomegalovirus Rh178 interrupts translation of major histocompatibility class I leader peptide-containing proteins prior to translocation R Richards, I Scholz, C Powers, WR Skach, K Früh Journal of virology 85 (17), 8766-8776, 2011 | 15 | 2011 |
| Discovery and intranasal administration of a SARS-CoV-2 broadly acting neutralizing antibody with activity against multiple Omicron subvariants JA Duty, T Kraus, H Zhou, Y Zhang, N Shaabani, S Yildiz, N Du, A Singh, ... Med 3 (10), 705-721. e11, 2022 | 13 | 2022 |
| Adenoviral assembly method C O'shea, C Powers US Patent 9,217,160, 2015 | 12 | 2015 |
| Chimeric mRNA-based COVID-19 vaccine induces protective immunity against Omicron and Delta variants Q Hu, Y Zhao, N Shaabani, X Lyu, C Powers, H Sun, V Cruz, K Stegman, ... Molecular Therapy-Nucleic Acids 30, 465-476, 2022 | 9 | 2022 |
| Synthetic adenoviruses with tropism to damaged tissue for use in promoting wound repair and tissue regeneration C O'shea, C Powers, L Zhang US Patent 11,730,781, 2023 | 5 | 2023 |
| Unbiased approach to identify and assess efficacy of human SARS-CoV-2 neutralizing antibodies X Cao, J Maruyama, H Zhou, Y Fu, L Kerwin, C Powers, RA Sattler, ... Scientific reports 12 (1), 15517, 2022 | 5 | 2022 |
| Exogenous gene expression in therapeutic adenovirus for minimal impact on viral kinetics C O'shea, W Partlo, C Powers US Patent 10,738,325, 2020 | 5 | 2020 |
| Synthetic adenoviruses targeting bone tissue and uses thereof C O'shea, C Powers, L Zhang US Patent App. 16/448,671, 2019 | 5 | 2019 |
| Anti-cancer adenoviruses C O'shea, C Powers US Patent 9,187,733, 2015 | 5 | 2015 |
